试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
编号:NCT00603941登记状态:提前终止企业 / 申办者:Daiichi Sankyo
药物 / 成分:CS-7017、Paclitaxel
登记的停止原因(原文):Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Effectiveness of Chinese Herbal Therapy for Asthma
编号:NCT00712296登记状态:提前终止企业 / 申办者:Icahn School of Medicine at Mount Sinai
药物 / 成分:ASHMI 4、ASHMI 12、Placebo
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
编号:NCT01801358登记状态:提前终止企业 / 申办者:Array Biopharma, now a wholly owned subsidiary of Pfizer
药物 / 成分:AEB071、MEK162
登记的停止原因(原文):The trial was terminated for scientific reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
编号:NCT02436135登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Idelalisib、Ruxolitinib
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
编号:NCT02997189登记状态:提前终止企业 / 申办者:Otonomy, Inc.
药物 / 成分:OTO-104
登记的停止原因(原文):Negative Efficacy Results from the recently completed Phase 3 study 104-201506
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
编号:NCT03116971登记状态:提前终止企业 / 申办者:EMD Serono Research & Development Institute, Inc.
药物 / 成分:M3814、Cisplatin、Etoposide
登记的停止原因(原文):Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the participants.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
编号:NCT03249272登记状态:提前终止企业 / 申办者:Duke University
药物 / 成分:Regadenoson、Adenosine
登记的停止原因(原文):Sponsor withdrew funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
PROMINENT-Eye Ancillary Study (Protocol AD)
编号:NCT03345901登记状态:提前终止企业 / 申办者:Jaeb Center for Health Research
药物 / 成分:Pemafibrate、Placebo
登记的停止原因(原文):recruitment for the substudy did not meet the goals
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Pegcetacoplan (APL-2) in Neovascular AMD
编号:NCT03465709登记状态:提前终止企业 / 申办者:Apellis Pharmaceuticals, Inc.
药物 / 成分:Pegcetacoplan
登记的停止原因(原文):Apellis concluded that sufficient data were collected to meet the study objectives.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-14
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
编号:NCT01466855登记状态:提前终止企业 / 申办者:Children's Hospital Medical Center, Cincinnati
药物 / 成分:Intra-Ophthalmic Artery Topotecan Infusion
登记的停止原因(原文):Competing studies
查看官方原始记录 ↗